Survival Outcomes After Liver Resection for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma Have Improved in the Contemporary Era
Hepatology Research · 2026-11 · 56 (11) · 1665-1675
DOI: 10.1111/hepr.70240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 09.07.2026. Verfasst von Yoichi Yamamoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Aim
The role of liver resection for Barcelona Clinic Liver Cancer stage B (BCLC‐B) hepatocellular carcinoma (HCC) remains debated. Advances in imaging and multidisciplinary therapy have improved outcomes in contemporary practice, in our institution over time. We evaluated era‐specific changes in survival after liver resection for BCLC‐B HCC and shifts in postrecurrence management.
Methods
This single‐center retrospective cohort analyzed consecutive patients undergoing curative liver resection for BCLC‐A and BCLC‐B disease ( n = 418 and 113) between 2005 and 2021. An exploratory minimum p ‐value approach based on 5‐year overall survival (OS) in BCLC‐B cases was used to determine a candidate cutoff for era stratification. Patients were divided into early and modern eras; survival outcomes were compared using propensity score matching.
Results
The 5‐year OS of BCLC‐B patients improved from 44% before 2014 to 74% after 2015 ( p < 0.05), whereas 5‐year disease‐free survival (DFS) increased from 5% to 22% ( p < 0.05). Postrecurrence management shifted toward greater use of radiofrequency ablation/percutaneous ethanol injection therapy and systemic therapy with tyrosine kinase inhibitors or immune checkpoint inhibitors, with a relative decline in transarterial chemoembolization. In the contemporary era, 5‐year OS of BCLC‐B approximated that of BCLC‐A (74% vs. 72%, p = 0.97), though DFS remained lower (22% vs. 45%, p < 0.05). Even after propensity score matching, the improvement in OS and DFS after 2015 remained significant ( p < 0.05).
Conclusions
Survival after liver resection for BCLC‐B HCC has improved substantially in the modern era, achieving 5‐year OS comparable to BCLC‐A. Resection should be considered for appropriately selected BCLC‐B patients within advanced multidisciplinary care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
- Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
ORCID-Profile: Yoichi Yamamoto, Yoh Asahi, Yuki Fujii, Yuzuru Sakamoto, Ken Imaizumi
Zitieren
APA
Yamamoto, Y., Asahi, Y., Shichi, S., Fujii, Y., Sakamoto, Y., Fujiyoshi, S., Imaizumi, K., Aiyama, T., Nagatsu, A., Orimo, T., Kakisaka, T., & Taketomi, A. (2026). Survival Outcomes After Liver Resection for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma Have Improved in the Contemporary Era. Hepatology Research, 56(11), 1665-1675. https://doi.org/10.1111/hepr.70240
Vancouver
Yamamoto Y, Asahi Y, Shichi S, Fujii Y, Sakamoto Y, Fujiyoshi S, et al. Survival Outcomes After Liver Resection for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma Have Improved in the Contemporary Era. Hepatology Research. 2026;56(11):1665-1675. doi:10.1111/hepr.70240
BibTeX
@article{Yamamoto2026,
author = {Yamamoto, Yoichi and Asahi, Yoh and Shichi, Shunsuke and Fujii, Yuki and Sakamoto, Yuzuru and Fujiyoshi, Sunao and Imaizumi, Ken and Aiyama, Takeshi and Nagatsu, Akihisa and Orimo, Tatsuya and Kakisaka, Tatsuhiko and Taketomi, Akinobu},
title = {Survival Outcomes After Liver Resection for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma Have Improved in the Contemporary Era},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {11},
pages = {1665--1675},
doi = {10.1111/hepr.70240}
}
EUVIMED